To the extent that statements contained in this press release are not descriptions of historical facts regarding Clovis Oncology, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the size of the offering, the conditions affecting the capital markets, general economic industry or political conditions, the uncertainties inherent in our clinical development programs for CO-101 and our other product candidates, the corresponding development pathways of our companion diagnostics, actions by the FDA, the EMA or other regulatory authorities regarding whether to approve drug applications that may be filed, as well as their decisions regarding drug labeling, and other matters that could affect the availability or commercial potential of our drug candidates or companion diagnostics, including competitive developments. Clovis Oncology does not undertake to update or revise any forward-looking statements. A further description of risks and uncertainties can be found in Clovis Oncology’s Registration Statement on Form S-1, as amended, filed with the SEC on March 30, 2012.

Copyright Business Wire 2010

If you liked this article you might like

Clovis Spikes on Phase 3 Data for Ovarian Cancer Drug- Biotech Movers

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

One of Wall Street's Hottest Biotech Stocks Tanks, Is Now the Time to Pounce?

Clovis Sell-Off May Be Overdone

Discovery, Clovis, Hertz Are Monday's Worst Performing Stocks -- Here's Why